• Johnson & Johnson received FDA accelerated approval for Rybrevant Faspro as a single-agent treatment for recurrent or metastatic head and neck cancer.
• Eligible adults must have progressed on or after platinum-based chemotherapy and an anti-PD-(L)1 antibody; HPV-associated oropharyngeal cancer is excluded.
• Continued approval may depend on confirmation of clinical benefit in the Phase 3 OrigAMI-5 trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.